Orlikowski D, Quijano-Roy S, Sivadon-Tardy V, Raphael J-C, Gaillard J-L
Service de Réanimation Médicale, Hôpital Raymond-Poincaré, 104, boulevard Raymond-Poincaré, 92380 Garches, France.
Arch Pediatr. 2006 Dec;13(12):1561-5. doi: 10.1016/j.arcped.2006.09.002. Epub 2006 Oct 9.
Guillain-Barre syndrome (GBS) is a rare disease triggered by postinfectious mechanisms. The disease concerns all ages, and is widely distributed around the world. The principal risks are respiratory failure, especially during the initial phase of the disease, and persisting deficit at long term. Among the infectious known agents, Campylobacter jejuni and CMV represent more than 40% of GBS causes. The clinical presentation, and the long-term prognosis of GBS related to these two etiologies are different. The physiopathological mechanisms of the nervous attack are probably also different. There is no proof, at this time, that anti-infectious treatment can improve the prognosis. The treatment is based on the early use of immunomodulatory treatments like intravenous immunoglobulins or plasma exchanges.
吉兰-巴雷综合征(GBS)是一种由感染后机制引发的罕见疾病。该疾病涉及所有年龄段,在全球广泛分布。主要风险是呼吸衰竭,尤其是在疾病初期,以及长期存在的功能缺陷。在已知的感染病原体中,空肠弯曲菌和巨细胞病毒占GBS病因的40%以上。与这两种病因相关的GBS的临床表现和长期预后有所不同。神经攻击的生理病理机制可能也不同。目前尚无证据表明抗感染治疗能改善预后。治疗基于早期使用免疫调节治疗,如静脉注射免疫球蛋白或血浆置换。